Company intelligence / Profile preview

Viveve Medical

Ownership: Private
Development stage: Commercial

Overview

Viveve Medical developed and commercialized the GENEVEVE™ system—a cryogen-cooled monopolar radiofrequency device designed to improve vaginal laxity and sexual function by stimulating neocollagenesis. The company conducted multiple clinical trials demonstrating safety and efficacy. However, as of mid-to-late 2023, the company ceased operations following unsuccessful attempts to secure additional financing or strategic alternatives.

Therapeutic areas: Men's HealthWomen's Health
Modalities: DeviceNon-pharmacological therapy (radiofrequency-based medical device)
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed

Beyond the preview

Go deeper on Viveve Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viveve Medical.

Explore the full profile